By: TechVanguard – SeaPRwire – Most labs still struggle to catch KIT D816V when it sits below one in a thousand alleles. Rarity Bioscience just put a kit on the table that claims to go lower. The superRCA Ultra-Sensitive KIT D816V Kit RUO targets less than 0.001 percent variant allele frequency. Launch date is 17 September 2026 out of Uppsala. Commercial availability is set for October. The assay is research-use only. Collaboration credits go to experts from Blueprint Medicines, a Sanofi company, and systemic mastocytosis specialists. That is the core claim.
Official performance numbers stay narrow. The assay quantifies the KIT D816V mutation, the primary driver in systemic mastocytosis. Levels in peripheral blood are often tiny. The kit uses Rarity’s proprietary superRCA technology. It runs on standard flow cytometers. No new capital equipment is required. Linus Bosaeus, the company’s chief executive, frames the launch as part of a wider push for rare-signal detection that remains accessible to ordinary labs. He links it to better biological insight and faster diagnostic and therapy development. Ben Lampson of Blueprint Medicines notes that many patients carry a heavy symptom load even when circulating mutation levels stay low. He points to skin lesions, diarrhea, fatigue, bone pain and anaphylaxis. A cited study puts mean time from first symptoms to diagnosis at roughly six years. The partnership aims to speed non-invasive blood-based tests that improve detection of the same mutation.
Industry subtext sits in the workflow choice. Flow-cytometer compatibility removes the barrier of specialized sequencing hardware. That matters for labs that already own the instruments. Research-use status keeps the kit outside diagnostic claims for now. The collaboration with Blueprint and SM clinicians shaped the assay around real clinical pain points rather than pure analytical targets. Quantitative readout at ultra-low frequency expands the usable sample set to peripheral blood. That shift can change how researchers track disease biology and residual signals. No clinical trial data or regulatory clearance is claimed in the announcement. The product simply ships as a research tool next month.
The supply side of ultra-sensitive mutation kits rarely moves this fast from platform to catalog. Rarity is testing whether labs will adopt a flow-based route for a mutation that has long required deeper sequencing. Practical next step is straightforward. Watch early research papers that report actual detection rates with the kit. Those numbers will show whether the sub-0.001 percent claim holds outside the company’s own validation runs.
Author bio: TechVanguard, former technical director at major Silicon Valley biotech firms and independent analyst focused on molecular diagnostics platforms.